- Athersys, Inc. is a late-stage international biotechnology company focused on regenerative medicine, primarily stem cell therapy.
- Athersys's pipeline consists of one late-stage candidate, a stem cell therapy known as MultiStem, which Athersys believes can be used to treat various diseases/conditions including ARDS and Ischemic Stroke.
- Athersys's financial position seems risky in the short term with a 9m 2020 cash burn of -$45M (+77% 9m/9m) and cash as of 9m 2020 at only $62M.
- In summary, the author projects Athersys, Inc. as a "buy" at a 3-5 year price target of $16 (+725% upside).
For further details see:
Athersys: Risky Financial Position, But Promising Upside By FYE 2023